ClinicalTrials.gg
CompletedNCT00918866Updated Nov 24, 2020Results posted

A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure

A Phase 4 interventional study of Definity in Pulmonary Heart Disease, sponsored by Lantheus Medical Imaging. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-11-24.

Sponsored by Lantheus Medical Imaging (part of Lantheus Holdings, Inc.) · Phase 4, Interventional, and Diagnostic

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
32
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Pulmonary Heart Disease with a site in United States — 1 open to participants now, 1 under way, none of them phase 3. Pulmonary Heart Disease · United States.

Enrollment
7th of 11
32 · median 41
Started
2009
with 1 other
Phase 4
2 of 19
none open now
Registered
3rd of 19
by date
Lead sponsor
1 of 19
Lantheus Medical Imaging

Among the 19 studies in Pulmonary Heart Disease with a site in United States, this one is the 7th largest by enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2009, is one of 2 in phase 4, and was the 3rd registered.

Pulmonary Heart Disease

42 studies on the registry are indexed under Pulmonary Heart Disease; 6 are open to participants now.

Browse Pulmonary Heart Disease studies →

Open to participants now

1 of the 19 studies in Pulmonary Heart Disease with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Pulmonary Heart Disease studies recruiting now, 1 sets no upper age limit and none stop at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Pulmonary Heart Disease with a site in United States, or all of them as a file.
02

Study summary

The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.

Read the detailed description

This Phase IV safety study will provide safety data on potential systemic and pulmonary hemodynamic effects caused by the administration of DEFINITY® in patients who are to undergo right heart cardiac catheterization for clinical reasons. Using a right heart catheter for direct measurements of pulmonary artery hemodynamics will allow accurate assessments of potential alterations of the pulmonary vasculature. This will be further investigated by the inclusion of two patient populations, one with a baseline pulmonary artery pressure \< 35 mmHg, and one with elevated baseline pulmonary artery pressure. The addition of immune parameter measurements will assess a potential link between systemic and pulmonary alterations and potential immune reactions following DEFINITY® administration.

The inclusion of patients in this study is not based on a required echocardiogram with DEFINITY® administration because patients would be exposed to an unjustifiable risk of invasive right heart catheterization and are unlikely to consent to such a procedure. Therefore, patients undergoing heart catheterization for clinical reasons, or patients who are undergoing pulmonary artery hemodynamic assessments will be enrolled and receive DEFINITY® in this study.

03

Conditions studied

  • Pulmonary Heart Disease

Keywords

  • Phase 4
  • DEFINITY®
  • hemodynamics
  • pulmonary artery pressure
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Appropriate candidate scheduled to undergo right heart catheterization and measurement of pulmonary artery hemodynamics for clinical reasons
  • Be male or female above the age of 18
  • Female patients who no longer have
  • Women of Child-Bearing Potential(WOCBP) who:

    1. are not pregnant and have been using an adequate and medically approved method of
    2. have a negative urine pregnancy test
  • Be able and willing to communicate effectively with study center personnel.

Exclusion criteria

Exclusion Criteria:

  • Women who are pregnant or lactating
  • Known or to or greater heart block
  • Previous heart transplant
  • Known right-to-left shunt (including atrial septal defect)
  • Severe pulmonary artery hypertension (i.e., > 75 mmHg
  • Current uncontrolled ventricular tachycardia
  • Second-degree or greater heart block
  • Any contraindications for the use of a right heart catheter
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Low Pulmonary Arterial Pressure

    Subjects with pulmonary arterial pressure (PAP) of \< or = to 35 mmHg.

    Drug: Definity

  • Experimental
    Elevated Pulmonary Arterial Pressure

    Subjects with a PAP of \> or = to 35 mmHg.

    Drug: Definity

Interventions

  • one bolus dose of Definity per intravenous injection, 30-60 second injection, dose value calculation = maximum of 10 microliter/kg patient weight

    Also known as: Perflutren Lipid Microsphere

06

What researchers measure

Primary outcomes

  1. Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose

    Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose

    Time frame: 31-35 minutes minus baseline

Secondary outcomes

  1. Immunology Panel- Complement 3A (C3A)

    Evaluate the Immunology Panel after the administration of DEFINITY

    Time frame: Out to 70 minutes

  2. Immunology Panel- Complement 5A(C5A)

    Evaluate the Immunology Panel after the administration of DEFINITY

    Time frame: Out to 70 minutes

  3. Immunology Panel- Interleuken-6

    Evaluate the Immunology Panel after the administration of DEFINITY

    Time frame: Out to 70 minutes

  4. Immunology Panel- Tryptase

    Evaluate the Immunology Panel after the administration of DEFINITY

    Time frame: Out to 70 minutes

07

Results

Posted Jul 11, 2011

Participant flow

participants were recruited from hospitals and clinics in the USA between July 2009 and December 2009

Participant flow — Overall Study
MilestoneLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Started1616
Completed1616
Not completed00

Outcome measures

PrimaryPercent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose

Percent change in pulmonary atery pressure change from immediately pre-dose to 31 - 35 minutes post dose

Time frame:
31-35 minutes minus baseline
Reported as:
Mean · mm Hg
Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose
mm HgLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Percent Change in Pulmonary Artery Pressure Change From 1 Minute Pre-dose to 31 - 35 Minutes Post Dose-1.9 ± 18.03-1.7 ± 10.25
SecondaryImmunology Panel- Complement 3A (C3A)

Evaluate the Immunology Panel after the administration of DEFINITY

Time frame:
Out to 70 minutes
Reported as:
Mean · ng/ml
Immunology Panel- Complement 3A (C3A)
ng/mlLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Immunology Panel- Complement 3A (C3A)-45.80 ± 338.14-38.20 ± 414.86
SecondaryImmunology Panel- Complement 5A(C5A)

Evaluate the Immunology Panel after the administration of DEFINITY

Time frame:
Out to 70 minutes
Reported as:
Mean · ng/ml
Immunology Panel- Complement 5A(C5A)
ng/mlLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Immunology Panel- Complement 5A(C5A)-0.95 ± 3.560.78 ± 4.55
SecondaryImmunology Panel- Interleuken-6

Evaluate the Immunology Panel after the administration of DEFINITY

Time frame:
Out to 70 minutes
Reported as:
Mean · pg/ml
Immunology Panel- Interleuken-6
pg/mlLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Immunology Panel- Interleuken-60.31 ± 1.460.15 ± 2.11
SecondaryImmunology Panel- Tryptase

Evaluate the Immunology Panel after the administration of DEFINITY

Time frame:
Out to 70 minutes
Reported as:
Mean · ug/ml
Immunology Panel- Tryptase
ug/mlLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
Immunology Panel- Tryptase-0.24 ± 0.82-0.01 ± 1.46

Adverse events

Collected over Through 32 hours. Non-serious events are listed at a 0.5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Low Pulmonary Arterial Pressure—0/16 (0%)4/16 (25%)
Elevated Pulmonary Arterial Pressure—0/16 (0%)5/16 (31.3%)
Most frequent other events
Most frequent other events
EventLow Pulmonary Arterial PressureElevated Pulmonary Arterial Pressure
MyalgiaMusculoskeletal and connective tissue disorders2/163/16
Chest PainGeneral disorders0/161/16
Back PainMusculoskeletal and connective tissue disorders1/161/16
Neck PainMusculoskeletal and connective tissue disorders0/161/16
DizzinessNervous system disorders1/160/16
HeadacheNervous system disorders1/160/16

Baseline characteristics

Age, Continuous
Age, Continuous(years)Low Pulmonary Arterial PressureElevated Pulmonary Arterial PressureTotal
Mean56.9 ± 10.857.4 ± 15.157.2 ± 12.9
Sex: Female, Male
Sex: Female, Male(Participants)Low Pulmonary Arterial PressureElevated Pulmonary Arterial PressureTotal
Female10717
Male6915
Pulmonary artery pressure 1 minute pre-dose
Pulmonary artery pressure 1 minute pre-dose(mm Hg)Low Pulmonary Arterial PressureElevated Pulmonary Arterial PressureTotal
Mean30.4 ± 3.3850.9 ± 10.3140.7 ± 12.89
08

Study locations

8 sites
  • Northwestern Memorial Hospital
    Chicago, Illinois 60611, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Methodist Hospital
    Saint Louis Park, Minnesota 55426, United States
  • Cardiovascular Consultants
    Kansas City, Missouri 64111, United States
  • Holy Name Hospital
    Teaneck, New Jersey 07666, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • Oregon Health and Sciences University
    Portland, Oregon 97239, United States
  • The University of Texas Medical Branch at Galveston
    Galveston, Texas 77555, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2009, a primary completion of Dec 2009 and a completion of Dec 2009. It does not say whether these dates are actual or estimated.

Results were first posted in Jul 2011, 1 year 7 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 4, 2009
First posted
Jun 11, 2009
Start
Jul 2009
Primary completionActual
Dec 2009
CompletionActual
Dec 2009
Results first posted
Jul 11, 2011
Last update
Nov 24, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 24, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00918866
Responsible party
Sponsor
First posted
Jun 11, 2009
Start date
Jul 2009
Primary completion
Dec 2009
Completion
Dec 2009
Results posted
Jul 11, 2011
Last update
Nov 24, 2020

Study contacts

Veronica Lee, MD
study director · Lantheus Medical Imaging

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Perflutren

Start the discussion